跳转至内容
Merck
CN
  • Architectural control of metabolic plasticity in epithelial cancer cells.

Architectural control of metabolic plasticity in epithelial cancer cells.

Communications biology (2021-03-21)
Maia Al-Masri, Karina Paliotti, Raymond Tran, Ruba Halaoui, Virginie Lelarge, Sudipa Chatterjee, Li-Ting Wang, Christopher Moraes, Luke McCaffrey
摘要

Metabolic plasticity enables cancer cells to switch between glycolysis and oxidative phosphorylation to adapt to changing conditions during cancer progression, whereas metabolic dependencies limit plasticity. To understand a role for the architectural environment in these processes we examined metabolic dependencies of cancer cells cultured in flat (2D) and organotypic (3D) environments. Here we show that cancer cells in flat cultures exist in a high energy state (oxidative phosphorylation), are glycolytic, and depend on glucose and glutamine for growth. In contrast, cells in organotypic culture exhibit lower energy and glycolysis, with extensive metabolic plasticity to maintain growth during glucose or amino acid deprivation. Expression of KRASG12V in organotypic cells drives glucose dependence, however cells retain metabolic plasticity to glutamine deprivation. Finally, our data reveal that mechanical properties control metabolic plasticity, which correlates with canonical Wnt signaling. In summary, our work highlights that the architectural and mechanical properties influence cells to permit or restrict metabolic plasticity.

材料
产品编号
品牌
产品描述

Roche
不含EDTA的cOmplete Mini蛋白酶抑制剂混合物, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Sigma-Aldrich
3-(三甲氧基甲硅基)甲基丙烯酸丙酯, 98%
Sigma-Aldrich
抗 α-微管蛋白单克隆抗体 小鼠抗, clone DM1A, ascites fluid